AAV204 is a novel adeno-associated virus (AAV) capsid from the AIM capsid library licensed by Abeona from the University of ...

Lupin Limited secures FDA approval for Loteprednol Etabonate Ophthalmic Gel, enhancing treatment options for postoperative ...

New technologies and a proactive mindset are transforming how glaucoma is diagnosed and treated—and redefining what ...

The program allows patients to undergo genetic testing and high-resolution retinal imaging anonymously and provide insights ...

Nicox completed the Denali Phase 3 trial for NCX 470, targeting open-angle glaucoma and ocular hypertension. NCX 470 combines ...

Yesafili is a VEGF inhibitor indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD), ...

In addition to Prevent Blindness’s usual free resources, the organization is providing a dedicated webpage, fact sheets, and ...

Sanaregen Vision Therapeutics invites investors to reserve shares as it prepares for an equity crowdfunding campaign to ...

Nanoscope Therapeutics formed the Vision Advisory Committee to guide its efforts in retinal care, focusing on retinitis ...

Through the program, gene therapies are developed to treat patients with retinitis pigmentosa caused by pathogenic variants ...

PYC Therapeutics advances VP-001 for retinitis pigmentosa, gaining FDA insights for its upcoming registrational trial.

RGN-259 is a thymosin beta-4–based eye drop designed to rival Dompé’s Oxervate, the only FDA-approved prescription eye drop ...